Clinical Trial Update: An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy, safety, tolerability, and pharmacokinetics of 12 weeks of Simeprevir plus Daclatasvir in chronic hepatitis C genotype 1b …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Hepatitis C

Drugs mentioned

• Daklinza (Daclatasvir)
• Olysio (Simeprevir)

Snippet

Sponsor: Janssen R&D Ireland | Conditions: Renal Impairment, End-stage Renal Disease | Phase 2 | Status: WITHDRAWN